Open AccessBisphosphonate-related osteonecrosis of the jaw: An insight
Author(s) -
Shalini Kapoor,
Geetanjali Sikka,
Pallak Arora,
Pradeep Chaudhary
Publication year - 2013
Publication title -
journal of orofacial sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.171
H-Index - 6
eISSN - 2320-4737
pISSN - 0975-8844
DOI - 10.4103/0975-8844.124248
Subject(s) - medicine , osteonecrosis of the jaw , osteoclast , bone remodeling , bisphosphonate , osteoporosis , bone resorption , vascularity , dentistry , osteomyelitis , resorption , bone density conservation agents , skeletal disorder , surgery , bone density , receptor
Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. They are effective in multiple clinical settings including postmenopausal osteoporosis, low bone mass in men, and drug-induced bone loss. Bisphosphonate-associated osteonecrosis of jaws (BRONJ) may result in serious oral complications, such as osteomyelitis and chronic exposure of necrotic bone. Dentists must be familiar with this disorder and pay special attention to all patients on bisphosphonate therapy due to their defective osteoclast function and reduced osseous tissue vascularity, leading to impaired wound healing and progressive necrosis of jaw bones. The purpose of this article is to review the history and pathogenesis of BRONJ, provide guidance to dentists on possible measures to prevent and manage patients with BRONJ